In the Competition Commission Appeal Tribunal ruling in Napp v DGFT, the Office of Fair Trading won a significant victory. Mark Friend discusses the implications for competition policy, particularly with regard to the pharmaceuticals sector
The Competition Commission Appeal Tribunal ruling on 15 January in Napp v DGFT is a significant victory for the OFT. Having lost the very first case to be appealed to the tribunal (GISC), a second defeat before the tribunal would have been a major embarrassment. In the event, although Napp succeeded in having its fine reduced from £3.21m to £2.2m, the tribunal supported the OFT on nearly all points of substance.
This premium content is reserved for
Legal Week Subscribers.
A PREMIUM SUBSCRIPTION PROVIDES:
- Trusted insight, news and analysis from the UK and across the globe
- Connections to senior business lawyers within the leading law firms and legal departments
- Unique access to ALM's unrivalled, market-leading reporting in the US and Asia and cutting-edge research, including Legal Week's UK Top 50 and Global 100 rankings
- The Legal Week Daily News Alert, Editor's Highlights, and Breaking News digital newsletters and more, plus a choice of over 70 ALM newsletters
- Optimized access on all of your devices: desktop, tablet and mobile
- Complete access to the site's full archive of more than 56,000 articles
Already have an account? Sign In Now
For enterprise-wide or corporate enquiries, please contact Paul Reeves on Preeves@alm.com or call on +44 (0) 203 875 0651